Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Bassand, J.-P.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Bassand, J.-P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2008. For permissions please email: journals.permissions@oxfordjournals.org

Unmet needs in antiplatelet therapy

Jean-Pierre Bassand*

Department of Cardiology, University Hospital Jean Minjoz, EA3920, 25000 Besançon, France

* Corresponding author. Tel: +33 381 66 85 39; fax: +33 381 66 85 82. E-mail address: jpbassan{at}univ-fcomte.fr

Despite antiplatelet therapy, patients with acute coronary syndromes (ACS) and those undergoing coronary intervention continue to experience atherothrombotic events, indicating a need for improvement in both overall patient management and antiplatelet treatments. Limitations of clopidogrel, which is widely used in dual therapy with aspirin, include slow onset of effect, low inhibition of platelet aggregation (IPA) in many patients, interindividual variability in response, and irreversible P2Y12 binding that prevents rapid offset of effect. Higher doses of clopidogrel may overcome some of these issues, and new oral agents such as the thienopyridine prasugrel and the reversible P2Y12 antagonist AZD6140 have faster onset of action and produce greater IPA. However, antiplatelet treatment must strike a balance between reduced atherothrombotic risk and bleeding risk, and it has yet to be determined whether greater platelet inhibition will produce better clinical outcome in terms of ischaemic events with an acceptable bleeding profile. Bleeding is an inherent risk of antiplatelet therapy and an independent predictor of poor prognosis in ACS patients, a factor that should be taken into account in assessing risks and benefits of antiplatelet treatment. New reversible P2Y12 antagonists offer the potential to discontinue antiplatelet therapy closer to invasive procedures compared with the thienopyridines, thus potentially reducing both procedure-related bleeding rates and duration of exposure to atherothrombotic risk prior to procedures. Ongoing large-scale Phase 3 trials will provide important information on whether the strategies of achieving higher levels of P2Y12 inhibition and using reversible inhibitors can improve antiplatelet therapy.

Key Words: AZD6140 • Acute coronary syndromes • CABG • Clopidogrel resistance


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.